Embracing a One Health Framework to Fight Antimicrobial Resistance

Antimicrobial resistance (AMR) – the ability of microbes to resist antimicrobials - remains an alarming global health threat that jeopardises the effectiveness of many 20th century public health advances. The latest OECD analysis shows that across 34 OECD and EU/EEA countries, AMR is estimated to claim more than 79 thousand lives every year, with the annual costs to health systems nearing USD PPP 29 billion. Adopting a multisectoral approach called the One Health framework is vital to tackling the complex drivers of AMR across human health, animal health, agrifood systems and the environment.

In recent years, the United States made important strides in tackling AMR. Yet, more progress is needed:

Resistance proportions for 12 antibiotic-bacterium pairs increased slightly between 2005 and 2019 (23.4% vs 24.5%) and averaged above the OECD average (20.8% in 2019). Resistance proportions are projected to decline slightly to 23.7% by 2035, averaging above the expected OECD average (20%).

Without further policy action, resistance proportions for third-generation cephalosporin-resistant *Escherichia coli* and fluoroquinolone-resistant *Escherichia coli* are expected to grow at the fastest pace between 2019 and 2035 (2.5 and 1 percentage points respectively). Growing resistance in these antibiotic-bacterium pairs can undermine the treatment of illnesses such as diarrhea, urinary tract infections and pneumonia.

Total antibiotic consumption in human health averaged at 28.2 defined daily dose (DDD) per 1 000 persons per day in 2015, below the OECD average (23.3). If trends persist, total antibiotic consumption is expected to increase considerably to 33 DDD per 1 000 persons per day by 2030, above the projected OECD average (22.5).

Access antibiotics – first- and second-line therapies with lower resistance potential – made up nearly 67% of all antibiotics consumed in the United States in 2015, exceeding the WHO target for Access antibiotics to make up at least 60% of national consumption.

AMR continues to pose a worrisome threat to population health and healthcare budget in the United States:

- **Deaths per 100 000 persons**
- **Annual per capita health expenditure USD PPP**

Unless resistant infections are eliminated, AMR is estimated to claim the lives of more than 24 052 persons each year.

AMR can cost USD 15 billion annually unless resistant infections are eliminated.

Note: The impact of AMR on population health is modelled by the OECD using two scenarios: 1) Elimination Scenario and 2) Replacement Scenario. The Elimination Scenario assumes elimination of all the resistant infections whereas the Replacement Scenario considers a situation where all resistant infections are assumed to be completely replaced by susceptible infections. Both scenarios are seen as plausible due to the dearth of concluding evidence in the literature.
The United States performs well in most policy areas but there is room for further policy action:

National AMR Action Plan

1 2 3 4 5

Optimising antimicrobial use in human health

1 2 3 4 5

Monitoring antimicrobial consumption in human health

1 2 3 4 5

Infection prevention and control (IPC) in human health

1 2 3 4 5

Training and education on AMR in human health

1 2 3 4 5

Biosecurity practices in terrestrial animal production

1 2 3 4 5

Good management and hygiene practices in food processing

1 2 3 4 5

The following priorities for action are identified to align policies with the Global Action Plan to Tackle AMR:

- Improving biosecurity practices by a) implementing a nationwide plan to ensure good animal husbandry and biosecurity best practices and b) implementation is regularly assessed.

In the United States, investing 4 USD per person annually in a mixed policy package can yield important gains every year:

<table>
<thead>
<tr>
<th>Infections prevented</th>
<th>Lives saved</th>
<th>Savings in healthcare costs (in billion USD)</th>
<th>Gains by increased workforce participation and productivity (in billion USD)</th>
<th>Return per USD invested</th>
</tr>
</thead>
<tbody>
<tr>
<td>683 546</td>
<td>9 369</td>
<td>4.8</td>
<td>8.3</td>
<td>9.86</td>
</tr>
</tbody>
</table>

Notes: 1 - least developed; 5 – most developed; diamonds indicate mode for OECD and EU/EEA countries; country scores are denoted in light blue.
Source: 2021-22 Tripartite AMR Self-Assessment Survey